Nuformix PLC Issue of Equity (4701Z)
10 Enero 2020 - 5:45AM
UK Regulatory
TIDMNFX
RNS Number : 4701Z
Nuformix PLC
10 January 2020
10th January 2020
Nuformix plc
("Nuformix" or "the Group"),
Issue of Equity
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs announces that following the receipt of Notice of
Exercise, 1,250,000 ordinary shares of 0.1p each in the Group (the
"Warrant Shares") have now been issued to the warrant holder
following exercise at the agreed price of 4p per share.
Application has been made to admit the Warrant Shares to trading
on the London Stock Exchange on 10 January 2020, and dealings in
the Warrant Shares are expected to commence on 14 January 2020
Following the issue of the Warrant Shares the total number of
shares now in issue is 490,145,083 ordinary shares with voting
rights attached (one vote per share). There are no shares held in
treasury.
This total voting rights figure may be used by shareholders as
the denominator for the calculations by which they will determine
whether they are required to notify their interests in, or a change
to their interest in, Nuformix plc under the Disclosure and
Transparency Rules.
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer
Email: info@nuformix.com +44 (0)1223 627222
Novum Securities Limited
Jon Belliss / Colin Rowbury +44 (0)20 7399 9427
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio of granted patents covering
cocrystal forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L.
About Fibrosis
Fibrotic disease is typically associated with high patient
mortality, increasing prevalence and a lack of safe and effective
treatments. Whilst, fibrosis treatments are in their infancy the
emerging lung fibrosis market demonstrates their blockbuster
potential. Markets for other fibrotic conditions are
under-developed, with large and growing patient populations (e.g.
the global liver disease market is predicted to reach $12.1 billion
by 2022). IPF is classified as a rare disease and presents a global
commercial market that is forecast to grow to $5bn by 2025.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEFZGMMMGRGGZM
(END) Dow Jones Newswires
January 10, 2020 06:45 ET (11:45 GMT)
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024